My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    BMS-8
    BMS-8

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V3256
    CAS #: 1675201-90-7Purity ≥98%

    Description: BMS-8 is an inhibitor of the PD-1 (Programmed death- 1)/PD-Ll (Programmed death-ligand 1) protein/protein interaction with potential anticancer activities. BMS-8 inhibits PD-1/PD-Ll interaction with IC50 of 146nM, and may augment therapeutic immune response to various histologically distinct tumors. Blockade of the PD-1/PD-Ll ligation using antibodies to PD-Ll has been shown to restore and augment T cell activation in many system. Structural basis for blocking the PD-1/PD-L1 interaction by small molecules is illustrated with the compound BMS-202 that binds to a hydrophobic cavity and induces dimerization of PD-L1.

    References:  2017 Jul 13;60(13):5857-5867;  2017 Aug 7;8(42):72167-72181;  WO/2015034820 A1


    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)494.43
    FormulaC27H28BrNO3 
    CAS No.1675201-90-7 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: >20 mg/mL  
    Water: N/A
    Ethanol: N/A
    SMILES CodeO=C(C1N(CC2=CC=C(OCC3=C(C)C(C4=CC=CC=C4)=CC=C3)C(Br)=C2)CCCC1)O
    Chemical Name1-[3-Bromo-4-(2-methyl-biphenyl-3-ylmethoxy)-benzyl]-piperidine-2-carboxylic acid 
    SynonymBMS-8; BMS 8; BMS8


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In VitroIn Vitro activity: BMS-8 is a inhibitor of the PD-1 (Programmed death- 1)/PD-Ll (Programmed death-ligand 1) protein/protein interaction with potential anticancer activities. BMS-8 inhibits PD-1/PD-Ll interaction, and may augment therapeutic immune response to various histologically distinct tumors. Blockade of the PD-1/PD-Ll ligation using antibodies to PD-Ll has been shown to restore and augment T cell activation in many system. 



    Kinase Assay: All binding studies are performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-l-Ig/PD-Ll-His binding assay, inhibitors are pre-incubated with PD-Ll-His (10 nM final) for 15 m in 4 μL of assay buffer, followed by addition of PD-l-Ig (20 nM final) in 1 μL of assay buffer and further incubation for 15 m. PD-L1 from either human, cyno, or mouse are used. HTRF detection is achieved using europium crypate-labeled anti- Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies are diluted in HTRF detection buffer and 5 μL is dispensed on top of binding reaction. The reaction mixture is allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) is obtained using an En Vision fluorometer. Additional binding assays are established between PD-1-Ig/PD-L2-His (20, 5 nM, respectively), CD80-His/PD-Ll-Ig (100, 10 nM, respectively) and CD80-His/CTLA4-Ig (10, 5 nM, respectively). 


    Cell Assay: The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction plays a dominant role in the suppression of T cell responses, especially in a tumor microenvironment, protecting tumor cells from lysis. PD-1/PD-L1 inhibitor 2 is reported to prevent the interaction of PD-L1 with PD-1 with an IC50 value of 18 nM.

    In Vivo
    Animal model
    Formulation & Dosage
    ReferencesNat Rev Cancer. 2012 Mar 22;12(4):252-64; WO 2015034820 A1


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    BMS-8

    Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.  2017 Aug 1;25(8):1163-1174.

     

    BMS-8

    New Directions in Designing the Therapeutics Targeting the PD-1/PD-L1 Interaction.  2017 Aug 1;25(8):1163-1174.

     

    BMS-8

    Structural Basis of the PD-1/PD-L1 (PD-L2) Interaction.  2017 Aug 1;25(8):1163-1174.

     BMS-8


     2017 Jul 13;60(13):5857-5867.

     

    BMS-8

     2017 Jul 13;60(13):5857-5867.

    BMS-8

     2017 Jul 13;60(13):5857-5867. 


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?